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who.int). Epilepsy is defined as two or more spontaneous 
seizures (WHO 2012; Fact sheet 999; www.who.int) and the 
development of this disorder (epileptogenesis) involves 
processes such as increasing network excitability (by 
increasing glutamate levels and sensitivity and reducing 
GABA inhibition), blood brain barrier breakdown, 
neuronal loss and mossy fibre sprouting [1]. Classical 
AEDs primarily target ion channels to prevent the hyper-
excitability that can lead to seizures, and ultimately exert 
their effect by raising the seizure threshold. Therefore, 
despite the nomenclature, AEDs are purely symptomatic 
and exhibit no disease-modifying potential. Recent 
studies using rodent models of seizures and epilepsy 
are uncovering other pathways, particularly involving 
inflammation, that may be implicated in both initiation 
and exacerbation of this disorder. Immunomodulatory 
AEDs represent a potentially novel avenue for drug 
development, not only to alleviate seizures but also to 
target the epileptogenic process [2].
2  Inflammation in epilepsy
Inflammation is classically described as a beneficial 
process to remove pathogens and aid healing. However, 
it is now also known to contribute to a range of central 
nervous system (CNS) disorders including Alzheimer’s 
disease, Parkinson’s disease, stroke, and epilepsy [2–4]. 
Seizures themselves can induce inflammation through the 
up-regulation of cytokines, chemokines, prostaglandins, 
toll-like receptors (TLRs), complement and cell adhesion 
molecules [5]. Inflammation not triggered by a pathogen 
is termed ‘sterile inflammation’. During a sterile insult, 
endogenous danger signals (damage associated molecular 
patterns; DAMPs) such as ATP, monosodium urate 
crystals, amyloid beta, or cholesterol crystals can induce 
the formation of a multi molecular protein complex termed 
an inflammasome. Recent evidence also suggests that 
cell swelling and the associated decrease in intracellular 
K+ and Cl- that can occur during seizures also activates 
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1  Introduction
Epilepsy affects people of all ages, sex and ethnicity and 
has been recognised since the earliest medical writings, 
yet despite more than 20 currently available antiepileptic 
drugs (AEDs) on the market, almost one third of sufferers 
are resistant to treatment (WHO 2012; Fact sheet 999; www.
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the inflammasome [6]. Activation of the inflammasome 
results in the release of pro-inflammatory cytokines that 
drive inflammation [3]. 
3  The inflammasomes
Inflammasomes are typically expressed in myeloid cells 
and form part of the innate immune system. They contain 
pattern recognition receptors (PRRs) that respond to danger 
signals through the detection of pathogen associated 
molecular patterns (PAMPs) or DAMPs. The PRRs contain 
a central nucleotide-binding and oligomerisation (NACHT) 
domain, a C-terminus leucine rich repeat (LRR) for ligand 
sensing and autoregulation, and an N-terminus caspase 
activation and recruitment domain (CARD) or a pyrin 
domain (PYD) for binding adaptor and effector proteins 
[7]. The type and combination of these components 
determines the inflammasome formed. The inflammasome 
that is activated by DAMPs under sterile conditions (such 
as may occur during epilepsy) is the NACHT, LRR and 
PYD-containing protein 3 (NLRP3) inflammasome. This 
comprises the PRR NLRP3, the adaptor protein apoptosis-
associated speck-like protein containing a CARD (ASC), 
and pro-caspase-1. In the brain, the NLRP3 inflammasome 
is primarily expressed in microglial cells. There is also some 
suggestion of NLRP3 function in neurons but this has not 
been confirmed [8]. Formation of the NLRP3 inflammasome 
causes the activation of caspase-1 which can then cleave the 
precursor of the pro-inflammatory cytokine interleukin-1 
beta (pro-IL-1β) into its biologically active form (IL-1β) [7]. 
Recently the NLRP3 inflammasome has also been shown 
to exert pro-inflammatory, yet IL-1-independent, effects 
including regulating the release of High Mobility Group 
Box-1 (HMGB1) [9]. 
4  High Mobility Group Box-1
HMGB1 is a 25KDa highly conserved protein comprising 
three major protein domains; two DNA binding regions 
(termed the A and B boxes) and a 30 amino acid acidic 
carboxyl terminus [10]. Discovered 30 years ago [11], it has 
myriad intracellular and extracellular functions. Primarily 
nuclear, HMGB1 bends DNA and regulates transcription. 
In all cells, HMGB1 continuously shuttles between the 
nucleus and cytoplasm. Acetylation of HMGB1 near the 
nuclear localization sequences blocks communication with 
the nuclear importer and inhibits re-entry into the nucleus 
[12]. HMGB1 can be passively released during necrosis but 
active secretion also occurs from immune cells in response 
to injurious stimuli following inflammasome activation [13, 
14]. Once outside the cell, HMGB1 acts as a potent DAMP 
to induce inflammation by signalling through TLR4 [15]. 
HMGB1 contains three conserved cysteine residues (C23, 
C45 and C106). Post-translational modifications of these 
residues critically regulate the protein’s function. Fully 
reduced all-thiol HMGB1 acts as a potent chemo-attractant 
through complex formation with CXCL12 binding exclusively 
via CXCR4 [16], whereas the cytokine stimulating activity of 
HMGB1 depends upon disulphide linkage between cysteine 
23 and cysteine 45, with cysteine 106 reduced as a thiol. Only 
in this configuration can HMGB1 trigger an inflammatory 
response via TLR4 [16, 17].  
5  Interleukin-1β
IL-1β is the most widely studied of the IL-1 family and 
was initially described as the endogenous pyrogen for its 
role in fever [18]. Since then, a number of physiological 
and pathological roles for IL-1 have been described 
[4]. Background levels of IL-1β are low but following 
pathogenic insult or stimulation with tumour necrosis 
factor alpha (TNFα) or even IL-1 itself, synthesis of pro-IL-1β 
is induced [19]. Following activation of IL-1β via the NLRP3 
inflammasome and caspase-1, mature IL-1β is released, by 
an as yet unconfirmed mechanism. Following release, IL-1β 
acts on its receptor IL-1R1 to induce gene transcription of 
cytokines, chemokines and adhesion molecules to further 
promote the pro-inflammatory cascade [4]. 
As described earlier, activation of the NLRP3 
inflammasome induces release of both IL-1β and HMGB1 
(Figure 1) [7, 9]. In addition, IL-1β itself can induce HMGB1 
release [20], and together,  IL-1β and HMGB1 have been 
shown to act synergistically to release IL-6 from synovial 
fibroblasts [21]. This suggests that targeting the NLRP3 
inflammasome may provide a means to abolish this 
inflammatory circuit; and targeting upstream of both IL-1β 
and HMGB1 in this way may achieve a more diverse anti-
inflammatory effect over targeting further down the IL-1 
cascade (i.e. with IL-1R1 antagonists or IL-1 antibodies). For 
example, anti-IL-1 therapies are not completely effective 
against cryopyrin-associated periodic syndrome caused 
by mutations in the NLRP3 gene, whereas targeting higher 
up the pathway with caspase-1 knock-outs is [22]. However, 
NLRP3 activation is not the only means of stimulating IL-1β 
or HMGB1 release, so although targeting inflammasome 
assembly may help to prevent the downstream cascade 
of events that can lead to the development of an epileptic 
focus, it may prove necessary to also include a more 
targeted approach to individual inflammatory mediators 
(i.e. specifically blocking HMGB1 or IL-1β). 
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6  IL-1β and HMGB1 expression in 
seizures
The involvement of IL-1β, and more recently HMGB1, in 
seizures has been well established using both genetic 
and pharmacological tools. Following seizures, IL-1β and 
HMGB1 are primarily expressed in microglia, although 
HMGB1 is also found in neurons [23, 24]. IL-1β and IL-1R1 
are up-regulated as a result of seizures in a variety of 
experimental models, including those induced by electrical 
stimulation, kainate, bicuculline, and hyperthermia [23, 
25–27]. Elevated IL-1β and IL-1R1 have also been observed 
in brain tissue from patients with temporal lobe epilepsy 
and hippocampal sclerosis, and elevated IL-1β has been 
reported in cerebrospinal fluid (CSF) from children 
with febrile seizures [28, 29]. In addition to increased 
IL-1 expression in patients with temporal lobe epilepsy, 
increases in IL-1β and inflammasome components have 
also been observed in other seizure disorders such as 
Rasmussen’s encephalitis [30] and malformations of 
cortical development [31].
Similarly, increased immunostaining for HMGB1 and 
its receptors, TLR4 and Receptor for Advanced Glycation 
Endproducts (RAGE), has been demonstrated in the brain 
tissue of mice following induction of both kainate- and 
bicuculline-induced acute seizures and kainate-induced 
chronic epilepsy [24, 32]. Increased staining for HMGB1, 
TLR4 and RAGE, is detectable in an analogous pattern 
to that observed in mouse models of epilepsy in human 
hippocampal tissue obtained at surgery from patients with 
Figure 1: Inflammasome activation and release of HMGB1 and IL-1β. Injurious stimuli induce the release of damage associated molecular 
patterns (DAMPs; 1). DAMPs induce the formation of the NLRP3 inflammasome (2). Inflammasome formation induces caspase-1 activation 
(3). Caspase-1 cleaves pro-IL-1β into its active form and results in the release of IL-1β and HMGB1 (4). This causes transcription of inflamm-
atory genes and phosphorylation of the NR2B subunit of NMDA receptors leading to an increase in neuronal Ca2+ entry. NLRP3: NACHT, LRR 
and PYD-containing protein 3; ASC: apoptosis-associated speck-like protein containing a CARD; HMGB1: high mobility group box-1; IL-1β: 
interleukin-1β; Pro-IL-1β: precursor inactive form of IL-1β; Pro-caspase-1: precursor inactive form of caspase-1; Fully-reduced HMGB1, domi-
nant form in nucleus and cytoplasm, chemoattractant, no cytokine activity; Disulphide HMGB1, induces cytokine transcription and release 
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temporal lobe epilepsy and hippocampal sclerosis, and 
also in malformations of cortical development associated 
with intractable seizures [20, 24, 32, 33]. 
7  IL-1β and HMGB1 exacerbate 
seizures
Pre-treatment with intra-hippocampal IL-1β or HMGB1 
prior to treatment with bicuculline or kainate exacerbates 
seizures [25, 33, 34]. In contrast, intra-cerebral infusion of the 
endogenous IL-1R1 antagonist IL-1Ra or its over-expression 
in astrocytes delays seizure onset and reduces duration 
following kainate [35] or reduces seizure behaviour following 
bicuculline treatment or electrically-induced status 
epilepticus (SE) [34]. Seizure onset is also delayed in mice 
lacking IL-1R1 [35]. Similarly, selective inhibition of HMGB1 
or TLR4 delays seizure onset and decreases seizure number 
and duration in both kainate- and bicuculline-induced acute 
seizure models and reduces the number of spontaneous 
epileptic seizures in the kainate model of chronic epilepsy 
[33]. Knock-out of TLR4 or RAGE is also anticonvulsant in 
kainate models of acute and chronic seizures [32]. Increased 
expression of IL-1β and HMGB1 in a variety of experimental 
models and clinical seizure disorders, in addition to their 
established pro-convulsant effects, provides evidence that 
targeting IL-1β and HMGB1 may prove successful in the 
treatment of epilepsy.
8  Pro-convulsant mechanisms of 
IL-1β and HMGB1
A fast signalling pathway has been characterised showing 
that IL-1R1 co-localises with the NR2A/B subunit of the 
NMDA receptor and IL-1β activation of this receptor results 
in phosphorylation of the NR2B subunit via Src kinases, 
resulting in increased neuronal Ca2+ influx [36].  Activation 
of this pathway in vivo using ceramide to activate Src 
kinases mimics the IL-1β-mediated exacerbation of 
kainate-induced seizures, whereas, inhibition of Src 
kinases has the opposite effect [37]. This fast signalling 
pathway has more recently also been described for 
HMGB1 [24]. The disulphide inflammatory form of HMGB1, 
but not its fully-reduced form, acts via TLR4 receptors 
to exacerbate kainate-induced seizures in a similar 
manner to that of IL-1β [38]. TLR4 receptors co-localise 
with NR1 and NR2B subunits of the NMDA receptor 
and disulphide HMGB1 enhances NMDA-mediated Ca2+ 
influx via neutral sphingomyelinase and Src kinases 
mediating phosphorylation of NR2B [38]. Thus activation 
of this fast signalling pathway has been proposed as one 
mechanism for the pro-convulsant effects of both IL-1β 
and HMGB1. Other potential excitotoxic mechanisms 
include increasing astrocytic glutamate release, reduction 
of glutamate uptake and increasing the translocation of 
AMPA receptors into neuronal membranes, [36, 39, 40].
9  IL-1β and HMGB1 as 
pharmacological targets
Pharmacological interventions targeting IL-1 and HMGB1 
are already in development for a number of disorders and 
could therefore also be potential treatments for seizures 
and epileptogenesis. The IL-1 receptor antagonist IL-1Ra, 
the anti-IL-1β neutralising antibody canakinumab, 
and the soluble decoy receptor rilonacept are already 
approved as treatments for rheumatoid arthritis and 
cryopyrin-associated periodic syndrome [19]. A number 
of successful strategies have also been shown to inhibit 
HMGB1 in experimental models, including polyclonal and 
monoclonal antibodies [41], competitive inhibition with 
the truncated HMGB1 A-Box [24], recombinant soluble 
thrombomodulin [42], and selective alpha7-nicotinic 
acetylcholine receptor agonists [43]. Indeed, nicotine 
has been shown to inhibit the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) pathway and 
to suppress HMGB1 release from human macrophages 
[43]. Antagonists that neutralize HMGB1 have also 
demonstrated considerable success in pre-clinical models 
of various diseases, including severe sepsis, arthritis, 
colitis, trauma and cancer. For example, administration of 
anti-HMGB1 antibodies, even where delayed by up to 24 
hours following cecal perforation in rodents, rescues the 
animals from otherwise lethal septicaemia [41, 44]. 
10  NLRP3 inflammasome, caspase-1 
and HMGB1 as anticonvulsant targets 
Consistent with the pro-convulsant actions of IL-1β and 
HMGB1, and the involvement of NLRP3 and caspase-1 
in the activity of both of these molecules, caspase-1 
inhibitors are anticonvulsant and knockout (KO) of the 
caspase-1 gene protects against seizure-inducing stimuli 
[45]. In the rat intrahippocampal kainate seizure model, 
pre-treatment with the caspase-1 inhibitors pralnacasan 
or VX-765 delayed seizure onset and decreased seizure 
number and time in seizures [45] (Table 1). In organotypic 
hippocampal slice cultures, both treatments also reduced 
IL-1β release [45]. These observations are supported by 
40   Michelle E. Edye, Lauren E. Walker, Graeme J. Sills, Stuart M. Allan, David Brough
Table 1: Anti-inflammatory therapies in experimental seizure models. 
Model Anti-inflammatory 
therapy
Target Timing (relative 
to brain insult)
Outcome Ref
Kainate seizure model; 
rat





IL-1Ra IL-1R1 Pre- and post- Reduction in seizure behaviour score.
Kainate seizure model; 
rat
Pralnacasan Caspase-1 Pre- Reduction in seizure-induced IL-1β.
Delay in seizure onset 
Reduction in seizure number and time in EEG 
seizure activity.
[45]
VX-765 Caspase-1 Pre- Delay in seizure onset.
Reduction in seizure number and time in EEG 
seizure activity.
Kainate and bicuculline 
seizure models;
mouse
Box A HMGB1 Pre- Delay in seizure onset.






Kainate  epilepsy 
model; mouse
Box A HMGB1 Post- Transient (2 hour) reduction in number and fre-
quency of spontaneous seizures.LPS-Rs TLR4
Pilocarpine and 
electrical model of 
epilepsy; rat
IL-1Ra and VX-765 IL-1R1 and 
caspase-1
Post- Reduction in IL-1β expression in astrocytes and 
cell loss in rat forebrain.




induced SE;  rat




Concomitant Acute delay seizure onset, decreased neuronal death.
Reduction spontaneous seizure frequency, mossy 
fibre sprouting.
[47]
KA-induced SE; mouse A438079 P2X7R Pre- and post- Reduction in EEG seizure activity and seizure 
behaviour score.
[49]
KA-induced SE; mouse A438079 P2X7R Pre Reduction in time in EEG seizure activity.
Reduction in cell death.
[50]
Brilliant blue G P2X7R Pre Reduction in time in EEG seizure activity.
Reduction in SE-induced IL-1β.
Reduction in reactive microglia.
Reduction in cell death.
anti P2X7R Ab P2X7R Pre Reduction in time in EEG seizure activity.
A438079 P2X7R Post- (15 mins) Reduction in time in EEG seizure activity and total 
power.
Reduction in cell death.
A438079 and lora-
zepam
P2X7R Post- (1 h) Reduction in time in EEG seizure activity and total 
power. 






Pannexin1 Pre- Increase in seizure behaviour score and power. [51]
OxATP, A438079, or 
A740003
P2X7R Pre- Increase in seizure behaviour score and power.
KA-induced SE; mouse MFQ Pannexin1 Pre- Reduction in seizure behaviour score. [52]
 
Key: IL-1β: Interleukin-1β; IL-1Ra: Interleukin-1 receptor antagonist; IL-1R1: Interleukin-1 receptor 1; LPS-Rs: Rhodobacter sphaeroides 
lipopolysaccharide; Cyp: cyanobacterial lipopolysaccharide; HMGB1: High mobility group Box-1; TLR4: toll-like receptor 4; SE: status 
epilepticus; P2X7R: P2X7 receptor
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data from the caspase-1 KO mouse model, which showed 
a delay in seizure onset and a decrease in seizure number 
and time in seizures [45]. Similarly, in mouse models 
of kainate- or bicuculline-induced seizures, targeting 
HMGB1 with the antagonist fragment Box A has been 
shown to postpone the onset and limit the duration of 
seizures in both acute and chronic phases of the response 
to convulsant challenge [24] (Table  1). It is possible, 
however, that these pre-insult therapies that have been 
shown to be effective at reducing acute seizures, may 
merely reflect a reduction in the extent of the initial 
insult caused by the chemoconvulsant, and may not 
be effective in targeting epileptogenesis.  Interestingly, 
when caspase-1 inhibitors and IL-1Ra treatment is given 
to rats after, rather than before, the epileptogenic insult 
(electrical stimulation or lithium-pilocarpine), the onset, 
frequency and duration of seizures in the chronic epileptic 
phase is unchanged. However, the combined post-
injury treatment does reduce forebrain IL-1β levels and 
ameliorates the degree of neuronal cell loss [46] (Table 1). 
Post-insult challenges such as this are the gold-standard 
method to define therapeutic anti-epileptogenic efficacy, 
as pre-insult therapies are not clinically realistic. These 
data therefore suggest that the timing of administration 
of immunomodulatory AEDs may be an important 
factor to consider; earlier post-injury intervention may 
be necessary to block the rapid inflammatory cascade. 
Alternatively, combinations of anti-inflammatory therapy, 
with or without standard AEDs, may be required [46]. 
Indeed, IL-1Ra with the COX-2 inhibitor CAY 10404 was 
effective at delaying seizure onset and reducing neuronal 
injury, whilst neither was effective alone [47]. When these 
treatments were given immediately prior to pilocarpine 
and for ten days post lithium/pilocarpine-induced SE, 
the frequency of spontaneous seizures was also reduced, 
but again a post-seizure effect of this anti-inflammatory 
combination has not been studied [47]. 
Directly targeting the NLRP3 inflammasome has yet to 
be explored but its inhibition may reduce caspase-1/IL-1β- 
and HMGB1/TLR4-mediated exacerbation of seizures. ATP-
mediated activation of the P2X7 receptor is well known 
to activate the NLRP3 inflammasome and recently this 
target has been investigated for its role in seizures [48]. 
P2X7 receptor antagonists reduce kainate-induced seizure 
behaviour [49] and seizure activity [50] and this effect is 
maintained even when administered 15 minutes after SE 
induction [50]. P2X7 receptor antagonists in combination 
with lorazepam halt SE when given 1 hour post SE, a 
time when neither is fully effective alone [50]. However, 
P2X7 antagonists are pro-convulsant in the pilocarpine 
seizure model [51]. Activation of P2X7 receptors opens 
a Pannexin1 pore but blocking this has again shown 
both pro- and anticonvulsant effects [51, 52]. Further 
work is required to explore the mechanisms of this P2X7 
receptor-mediated effect on seizures but as P2X7 receptor 
antagonists reduce SE-induced mature IL-1β production, 
the reduction in seizure activity may, at least in part, be 
due to inhibiting NLRP3 actions on IL-1β/HMGB1 [50]. 
Thus combinations of anti-inflammatory and standard 
AEDs may be therapeutically effective. Additionally, 
neutralisation of the inflammasome adapter protein ASC 
has been shown to be protective in mouse models of acute 
sterile brain injury (traumatic brain injury and spinal cord 
injury) [8] and therefore may provide an additional target 
for anti-inflammatory AEDs.
11  Conclusion
The cycle of seizures inducing inflammation and 
inflammation exacerbating seizures highlights the 
potential benefit of targeting constituents of the 
inflammatory cascade to halt this cycle and to treat seizures 
and epilepsy. The effectiveness in a variety of seizure 
models of targeting IL-1β and HMGB1 signalling suggests 
that the NLRP3 inflammasome could be a successful 
future target for the treatment of seizures and epilepsy. 
The caspase-1 inhibitor VX-765 has already undergone 
Phase II trials for partial epilepsy (http://clinicaltrials.
gov/ct2/show/NCT01048255), so the precedent has been 
set for safely targeting this pathway. As yet, no studies 
have specifically looked at inhibition of the NLRP3 
inflammasome as an alternative means of targeting 
inflammation associated with seizure disorders. However, 
with small molecule inhibitors now being synthesised, 
targeting the NLRP3 inflammasome as a common point in 
both IL-1β and HMGB1 pathways could result in improved 
treatments over more selective approaches and could 
potentially provide relief for patients with treatment 
resistant epilepsy.
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